Compare CubeSmart (CUBE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs State Street SPDR S&P Biotech ETF — how do they compare? CubeSmart trades at $37.93 (market cap $8.45B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and CubeSmart pays a 5.65% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CUBE | XBI | |
|---|---|---|
Market Cap | $8.45B | $10.11B |
Volume | 2,879,532 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $42.50 | $169.55 |
52-Week Low | $35.36 | $104.99 |
Typical Hold Time | 89 Days | 38 Days |
Enterprise Value | $11.97B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.97, up 1.99% on the day, with a bearish technical outlook as moving averages signal selling pressure. The company reported mixed Q2 2026 results, with an FFO miss but revenue beat, and maintains strong profitability with a 29.41% net income margin. Recent news highlights institutional accumulation, with firms like NewEdge Advisors and Deutsche Bank increasing stakes, while analyst consensus leans toward Hold with a $44.00 price target.
The stock offers a 5.4% dividend yield and trades below the consensus target, suggesting potential upside if operational improvements materialize. Risks include high leverage with $2.99B in long-term debt and sensitivity to real estate market cycles. Earnings growth in H2 2026 is critical for reversing the current bearish sentiment.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
